吉華集團(603980.SH):徐杏花競買2839.4萬股已完成過户
格隆匯5月11日丨吉華集團(603980.SH)公佈,杭州市中級人民法院於杭州市中級人民法院淘寶網司法拍賣網絡平台上對蕭然工貿持有的669.4萬股公司股份進行公開拍賣,用户姓名徐杏花以最高應價勝出。
公司近日從蕭然工貿處獲悉,徐杏花已完成本次司法拍賣的過户手續。截至本公吿日,徐杏花持有2839.4萬股公司股票,佔公司總股本的4.06%。
截至本公吿披露日,蕭然工貿持有公司的股份總數為420.2965萬股,佔公司總股本的0.6%。蕭然工貿目前所持公司股份均被司法凍結,佔其持有公司股份的100%,佔公司總股本的0.6%。本次司法拍賣完成過户不會導致公司的控股股東和實際控制人發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.